Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cardiovasc J Afr ; 33: 1-4, 2022 Dec 05.
Article in English | MEDLINE | ID: covidwho-20236195

ABSTRACT

This report describes two patients who presented with severe type B lactic acidosis and shock, initially thought to be due to bowel ischaemia/myocardial infarction and pulmonary sepsis, respectively. This led to a delay in the diagnosis of thiamine deficiency. In both cases there was a dramatic response to intravenous thiamine, confirming the diagnosis of Shoshin beriberi. Both patients admitted to drinking home-brewed alcohol during the time of COVID-19 restrictions on alcohol consumption. These cases highlight the need for early diagnosis and immediate empirical treatment with intravenous thiamine in patients presenting with unexplained severe metabolic acidosis and circulatory shock.

2.
Indian J Gastroenterol ; 42(2): 249-273, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2260566

ABSTRACT

The Indian Neurogastroenterology and Motility Association (INMA), earlier named the Indian Motility and Functional Diseases Association developed this evidence-based practice guidelines for the management of irritable bowel syndrome (IBS). A modified Delphi process was used to develop this consensus containing 28 statements, which were concerning diagnostic criteria, epidemiology, etiopathogenesis and comorbidities, investigations, lifestyle modifications and treatments. Owing to the Coronavirus disease-19 (COVID-19) pandemic, lockdowns and mobility restrictions, web-based meetings and electronic voting were the major tools used to develop this consensus. A statement was regarded as accepted when the sum of "completely accepted" and "accepted with minor reservation" voted responses were 80% or higher. Finally, the consensus was achieved on all 28 statements. The consensus team members are of the view that this work may find use in teaching, patient care, and research on IBS in India and other nations.


Subject(s)
COVID-19 , Gastroenterology , Irritable Bowel Syndrome , Humans , Adult , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/epidemiology , Irritable Bowel Syndrome/etiology , COVID-19/epidemiology , COVID-19/complications , Communicable Disease Control , Comorbidity
3.
Journal of Pharmaceutical Negative Results ; 13(4):848-851, 2022.
Article in English | EMBASE | ID: covidwho-2156305

ABSTRACT

Aim: In this investigation, we looked at how the COVID 19 pandemic affected the number, complication rates, and epidemic features of patients who had surgery at our facility for inguinal hernias. Method(s): We conducted a retrospective analysis of all patients who underwent inguinal hernia operations at the Department of General Surgery Meenakshi Medical College and Research Institute, Kanchipuram, between November 2020 and November 2021. The descriptive statistics employed were percentages, means, standard deviations, medians, and interquartile ranges. When comparing two groups, the Mann-Whitney U test was applied to changes that deviate from the normally distributed spectrum. The Pearson Chi-Square test and Fisher's Exact test were used to investigate the relationships between qualitative variables. For all statistical analyses, 0.05 was deemed to be the significant value. Result(s): 65 individuals (Group 1) underwent surgery between November 2020 and November 2021, and 26 patients between March 11, 2020, and 2021. (Group 2). In Group 2, there was a statistically significant rise in the rate of incarceration and strangulation (44.6% in Group 1, 84.6% in Group 2, p=0.008) as well as a statistically significant rise in the proportion of female patients (4.6% in Group 1, 23.1% in Group 2, p=0.008). Conclusion(s): The rate of detention and strangling increased as during COVID-19 pandemic. The precipitous decline in elective procedures or the rise in the proportion of female patients admitted during the COVID period can be blamed for the rise in complication rates. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.

4.
Gut ; 71(11): 2152-2166, 2022 11.
Article in English | MEDLINE | ID: covidwho-2020114

ABSTRACT

The Asia-Pacific region has the largest number of cases of colorectal cancer (CRC) and one of the highest levels of mortality due to this condition in the world. Since the publishing of two consensus recommendations in 2008 and 2015, significant advancements have been made in our knowledge of epidemiology, pathology and the natural history of the adenoma-carcinoma progression. Based on the most updated epidemiological and clinical studies in this region, considering literature from international studies, and adopting the modified Delphi process, the Asia-Pacific Working Group on Colorectal Cancer Screening has updated and revised their recommendations on (1) screening methods and preferred strategies; (2) age for starting and terminating screening for CRC; (3) screening for individuals with a family history of CRC or advanced adenoma; (4) surveillance for those with adenomas; (5) screening and surveillance for sessile serrated lesions and (6) quality assurance of screening programmes. Thirteen countries/regions in the Asia-Pacific region were represented in this exercise. International advisors from North America and Europe were invited to participate.


Subject(s)
Adenoma , Colonic Polyps , Colorectal Neoplasms , Adenoma/diagnosis , Adenoma/epidemiology , Adenoma/surgery , Asia/epidemiology , Colonoscopy , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/pathology , Consensus , Early Detection of Cancer , Humans
5.
Gut ; 71(12): 2401-2413, 2022 12.
Article in English | MEDLINE | ID: covidwho-1993046

ABSTRACT

OBJECTIVE: Microbiome and dietary manipulation therapies are being explored for treating ulcerative colitis (UC). We aimed to examine the efficacy of multidonor faecal microbiota transplantation (FMT) and anti-inflammatory diet in inducing remission followed by long-term maintenance with anti-inflammatory diet in patients with mild-moderate UC. DESIGN: This open-labelled randomised controlled trial (RCT) randomised patients with mild-moderate (Simple Clinical Colitis Activity Index (SCCAI) 3-9) endoscopically active UC (Ulcerative Colitis Endoscopic Index of Severity (UCEIS)>1) on stable baseline medications in 1:1 ratio to FMT and anti-inflammatory diet (FMT-AID) versus optimised standard medical therapy (SMT). The FMT-AID arm received seven weekly colonoscopic infusions of freshly prepared FMT from multiple rural donors(weeks 0-6) with anti-inflammatory diet. Baseline medications were optimised in the SMT arm. Clinical responders (decline in SCCAI>3) at 8 weeks in both arms were followed until 48 weeks on baseline medications (with anti-inflammatory diet in the FMT-AID arm). Primary outcome measures were clinical response and deep remission (clinical-SCCAI <2; and endoscopic-UCEIS <1) at 8 weeks, and deep remission and steroid-free clinical remission at 48 weeks. RESULTS: Of the 113 patients screened, 73 were randomised, and 66 were included in (35-FMT-AID; 31-SMT) modified intention-to-treat analysis (age-35.7±11.1 years; male-60.1%; disease duration-48 (IQR 24-84) months; pancolitis-34.8%; SCCAI-6 (IQR 5-7); UCEIS-4 (IQR 3-5)). Baseline characteristics were comparable. FMT-AID was superior to SMT in inducing clinical response (23/35 (65.7%) vs 11/31 (35.5%), p=0.01, OR 3.5 (95% CI 1.3 to 9.6)), remission (21/35 (60%) vs 10/31 (32.3%), p=0.02, OR 3.2 (95% CI 1.1 to 8.7)) and deep remission (12/33 (36.4%) vs 2/23 (8.7%), p=0.03, OR 6.0 (95% CI 1.2 to 30.2)) at 8 weeks. Anti-inflammatory diet was superior to SMT in maintaining deep remission until 48 weeks (6/24 (25%) vs 0/27, p=0.007). CONCLUSION: Multidonor FMT with anti-inflammatory diet effectively induced deep remission in mild-moderate UC which was sustained with anti-inflammatory diet over 1 year. TRIAL REGISTRATION NUMBER: ISRCTN15475780.


Subject(s)
Colitis, Ulcerative , Fecal Microbiota Transplantation , Male , Humans , Colitis, Ulcerative/therapy , Remission Induction , Diet , Anti-Inflammatory Agents , Treatment Outcome
6.
Indian J Gastroenterol ; 40(6): 613-620, 2021 12.
Article in English | MEDLINE | ID: covidwho-1560550

ABSTRACT

AIMS: Lockdown and restricted mobility due to the pandemic of corona virus disease  2019 (COVID-19) has severely affected the continuity of healthcare of patients with acute and chronic diseases. We evaluated the impact of COVID-19 on the adherence to gluten-free diet (GFD), symptom control, and quality of life (QOL) in patients with celiac disease (CeD). METHODS: A questionnaire, consisting of both ad-hoc and validated questions, was created after review of literature, group discussions, and expert meetings. Standardized questionnaires namely CeD adherence test (CDAT), celiac symptom index score, and CeD-related QOL were used. The web-based questionnaire was sent to 3130 patients via social media and 452 responses (14.4%) were received. Also, additional 68 patients (not available on any social media application) were interviewed telephonically by a trained dietitian. RESULTS: Overall, 505 patients (females: 318; mean age: 24.1±14.2 years) were included. While only 6.7% (n = 34) had poor compliance to GFD (CDAT > 17) before COVID-19 pandemic, it almost doubled to 12.6% (n = 64) during the COVID-19 pandemic times (p = 0.02). Furthermore, 4.9% (n = 25) of patients were diagnosed contacting  COVID-19. Interestingly, 73.2% (n = 370) patients preferred online appointment than physical appointment. Most common difficulties faced during lockdown period were high delivery charges for getting gluten-free (GF) food at home (54.4%), increased prices of regular GF food (43.1%), and travelling long distance to arrange GF food (44.9%). CONCLUSIONS: The COVID-19 pandemic has substantially affected the adherence, symptom control, and QOL in patients with CeD, attributable to unavailability, shortage of money, and heightened cost of GF food. The pandemic has offered an opportunity to practice teleconsultation approach for patients with CeD.


Subject(s)
COVID-19 , Celiac Disease , Adolescent , Adult , Celiac Disease/epidemiology , Child , Communicable Disease Control , Diet, Gluten-Free , Female , Humans , Pandemics , Patient Compliance , Quality of Life , SARS-CoV-2 , Young Adult
7.
JGH Open ; 4(3): 320-323, 2020 Jun.
Article in English | MEDLINE | ID: covidwho-592734

ABSTRACT

The COVID-19 pandemic, secondary to SARS-CoV-2, has resulted in high mortality and morbidity worldwide. As inflammatory bowel disease (IBD) is a chronic disease, and most patients are on long-term immunosuppressive agents, there is understandable concern, particularly in terms of therapy. In view of this, experts in IBD across the Asia Pacific region were invited to put together recommendations based on their experience and the currently available data. In general, most IBD therapies (with a few exceptions) can be continued safely, and the general consensus is that maintaining disease control should remain the main principle of management. In addition, social distancing measures and the appropriate use of personal protective equipment should be strictly adhered to. During the current pandemic, face-to-face clinic follow ups and non-urgent procedures should be kept to a minimum.

SELECTION OF CITATIONS
SEARCH DETAIL